Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Study finds metabolic dysfunction treatment useful for Alzheimer’s disease

Staff Writer
Staff Writer 3 years ago
Updated 2020/02/18 at 5:26 PM
Share
SHARE

Alzheimer’s disease, a neurodegenerative condition considered one of the most common causes of dementia in older adults, is theorized to be the result of an accumulation of amyloid-beta (Aβ) protein in the brain. In a new study, a team of researchers unveiled new evidence pointing to another theory: metabolic dysfunction.

According to a report, published in the journal eLife, researchers at Yale-NUS college in Singapore suggest that metabolic defects, occurring before any increase in amyloid-beta protein, could be a primary cause of Alzheimer’s disease.

In the study, researchers utilized Caenorhabditis elegans due to its resemblance to human cells at the molecular level. Upon administering metformin, a common treatment for type 2 diabetes, they found that the anti-diabetes drug significantly improved metabolic defects and strengthened the Caenorhabditis elegans’ lifespan.

“Treatment with an anti-diabetes drug, metformin, reversed Aβ-induced metabolic defects, reduced protein aggregation and normalized lifespan,” the findings indicated. “Our results point to metabolic dysfunction as an early and causative event in Aβ-induced pathology and a promising target for intervention.”

Jan Gruber, the study’s lead researcher, added: “Based on the emerging strong links between mitochondrial dysfunction and Alzheimer’s pathology, it might be better to adopt a preventative strategy by targeting metabolic defects, especially mitochondrial defects, directly and early, well before protein aggregates are even present.”

“Current trials of Alzheimer’s drugs targeting proteins have failed despite billions of dollars being invested.”

You Might Also Like

MIT study shows how microglia can contribute to Alzheimer’s disease

New paper refutes theory that the human brain shrank 3,000 years ago

New study finds that people with autism are more skilled at reading emotions in cartoons

New research suggests smartphone use may enhance memory skills

New report explores the link between dementia and air pollution

TAGGED: Alzheimer's disease, cognition, metabolic dysfunction
Staff Writer October 17, 2019
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Depression may increase the risk of Facebook addiction disorder
Next Article Diabetes is a major risk factor for respiratory infections, research suggests

Recommended

Clinical

MIT study shows how microglia can contribute to Alzheimer’s disease

1 Min Read
Clinical

New paper refutes theory that the human brain shrank 3,000 years ago

1 Min Read
Clinical

New study finds that people with autism are more skilled at reading emotions in cartoons

1 Min Read
Cyber

New research suggests smartphone use may enhance memory skills

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?